ResMed's Rocky Path to Recovery ResMed's recent quarterly results have sent shockwaves through the healthcare industry, but beneath the surface of declining stock prices lies a more complex story.
The company has been struggling for some time now, and its latest fiscal year guidance only serves as a reminder that even promising ventures can hit turbulence. With a market capitalization of $33.
5 billion, ResMed is a significant player in the industry, operating in 140 countries and offering innovative solutions aimed at improving sleep and breathing.